Division of Radiotherapy, ASST Valle Olona, Via A. da Brescia, 1, Busto Arsizio 21052 VA, Italy.
Division of Medical Physics, ASST Valle Olona, Via A. da Brescia, 1, Busto Arsizio 21052 VA, Italy.
Phys Med. 2024 Nov;127:104855. doi: 10.1016/j.ejmp.2024.104855. Epub 2024 Nov 2.
In the adjuvant right breast radiation therapy, after breast-conserving surgery, we wanted to look for a parameter that would help in the choice between the 3D-CRT or VMAT techniques, considering the risk of pneumonia to the ipsilateral lung (IL) linked to high doses. We also investigated the risk of second tumors in the IL related to the VMAT low doses.
We examined twenty-five 3D-CRT and thirty-five VMAT technique plans, between September 2022 and September 2023. We collected the MAximum Thickness of Ipsilateal Lung (MATIL) included between lateral and medial target borders for evaluating the risk of pneumonia due to the high dose (V), finally we calculated the Excess of Absolute Risk related to the second tumor risk due to the low dose.
VMAT technique showed a better dose conformity than 3D-CRT. We detected a linear relationship between the V and MATIL of the IL only for the 3D-CRT technique; over a threshold value of MATIL the 3D-CRT is disadvantaged compared to the VMAT in terms of the risk of toxicity to the IL. We calculated that for every Gy more in average dose, a 12 % increase in the risk of induced cancer is expected.
In the adjuvant right breast RT, the MATIL is a good surrogate parameter to predict the need to use a VMAT technique to limit high doses to IL. VMAT technique, according to the IL second tumor estimated risk, seems justified.
在保乳手术后的辅助右乳房放射治疗中,我们希望寻找一个参数,以便在考虑与高剂量相关的同侧肺(IL)肺炎风险的情况下,帮助选择 3D-CRT 或 VMAT 技术。我们还研究了与 VMAT 低剂量相关的 IL 第二肿瘤的风险。
我们检查了 25 例 3D-CRT 和 35 例 VMAT 技术计划,时间为 2022 年 9 月至 2023 年 9 月。我们收集了外侧和内侧靶区之间的最大同侧肺厚度(MATIL),用于评估高剂量(V)导致肺炎的风险,最后我们计算了与低剂量相关的第二肿瘤风险的绝对风险超额。
VMAT 技术比 3D-CRT 具有更好的剂量适形性。我们仅在 3D-CRT 技术中检测到 IL 的 V 和 MATIL 之间存在线性关系;超过 MATIL 的阈值值,与 VMAT 相比,3D-CRT 在 IL 毒性风险方面处于劣势。我们计算出,每增加平均剂量 1Gy,预计癌症诱导风险增加 12%。
在辅助右乳房 RT 中,MATIL 是预测需要使用 VMAT 技术限制 IL 高剂量的良好替代参数。根据估计的 IL 第二肿瘤风险,VMAT 技术似乎是合理的。